AR066913A1 - METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS - Google Patents

METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS

Info

Publication number
AR066913A1
AR066913A1 ARP080102431A ARP080102431A AR066913A1 AR 066913 A1 AR066913 A1 AR 066913A1 AR P080102431 A ARP080102431 A AR P080102431A AR P080102431 A ARP080102431 A AR P080102431A AR 066913 A1 AR066913 A1 AR 066913A1
Authority
AR
Argentina
Prior art keywords
heavy chain
light chain
methods
amino acid
variable region
Prior art date
Application number
ARP080102431A
Other languages
Spanish (es)
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of AR066913A1 publication Critical patent/AR066913A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Dichos anticuerpos anti-DR5 poseen inmunogenicidad minimizada en humanos. Métodos para usar dichos anticuerpos. Reivindicacion 1: Un anticuerpo que se une al Receptor do Muerte 5 (DR5), donde el anticuerpo comprende a) una region variable de la cadena pesada que comprende un segmento V humano de cadena pesada, una region determinante de la complementariedad 3 de cadena pesada (CDR3), y una region de marco de cadena pesada 4 (FR4) y (b) una region variable de la cadena liviana que comprende un segmento V humano de cadena liviana, una CD3 de cadena liviana y una FR4 de cadena liviana, donde i) La CD3 de CDR3 de cadena pesada comprendo la secuencia de aminoácidos HEEGI (SEC ID N°: 49) y ii) la region variable CD3 de la cadena liviana comprende la secuencia de aminoácidos QXHXXTP (SEC ID N°: 50), en la cual x indica cualquier aminoácido.Such anti-DR5 antibodies possess minimized immunogenicity in humans. Methods for using said antibodies. Claim 1: An antibody that binds to Death Receptor 5 (DR5), wherein the antibody comprises a) a heavy chain variable region comprising a heavy chain human segment V, a region determining heavy chain complementarity 3 (CDR3), and a heavy chain frame region 4 (FR4) and (b) a variable region of the light chain comprising a light chain human segment V, a light chain CD3 and a light chain FR4, where i) The heavy chain CDR3 CD3 comprising the HEEGI amino acid sequence (SEQ ID NO: 49) and ii) the CD3 variable region of the light chain comprises the amino acid sequence QXHXXTP (SEQ ID NO: 50), in which x indicates any amino acid.

ARP080102431A 2007-06-08 2008-06-06 METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS AR066913A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94286207P 2007-06-08 2007-06-08

Publications (1)

Publication Number Publication Date
AR066913A1 true AR066913A1 (en) 2009-09-23

Family

ID=39730803

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102431A AR066913A1 (en) 2007-06-08 2008-06-06 METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS

Country Status (4)

Country Link
AR (1) AR066913A1 (en)
PE (1) PE20090765A1 (en)
TW (1) TW200911835A (en)
WO (1) WO2008154439A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5878538B2 (en) 2010-08-27 2016-03-08 ギリアド バイオロジクス, インク.Gilead Biologics, Inc. Antibodies against matrix metalloproteinase 9
BR112014021477A2 (en) 2012-02-29 2018-06-12 Gilead Sciences Inc matrix metalloproteinase antibodies 9
US9732156B2 (en) * 2012-02-29 2017-08-15 Gilead Biologics, Inc. Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9
CN106397594B (en) * 2016-10-25 2019-06-04 中国药科大学 A kind of agonist single-chain antibody of the anti-human death receptor 5 of full source of people and application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
EP1539233B1 (en) * 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
BR0316737A (en) * 2002-11-27 2005-12-13 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
KR20070010046A (en) * 2004-04-06 2007-01-19 제넨테크, 인크. Dr5 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2008154439A1 (en) 2008-12-18
PE20090765A1 (en) 2009-07-10
TW200911835A (en) 2009-03-16

Similar Documents

Publication Publication Date Title
PE20140806A1 (en) HUMANIZED ANTI-FACTOR D ANTIBODIES AND THEIR USES
ES2657226T3 (en) Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody
AR079336A1 (en) ANTAGONISTS OF THE PRO-PROTEIN CONVERTASE-SUBTILISINE / TYPE 9 QUEXINE (PCSK9)
AR052889A1 (en) ANTIBODIES AGAINST INTERLEUQUINE-1 BETA
AR062213A1 (en) ANTIBODIES DIRECTED AGAINST (ALFA V BETA 6) AND USES OF THE SAME
PE20080035A1 (en) HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR TYPE KINASE-1
PE20141435A1 (en) NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
AR117913A2 (en) DRUG-ANTIBODY CONJUGATE, PHARMACEUTICAL COMPOSITION AND ITS USES
AR083747A1 (en) ANTI-IL-23 ANTIBODIES
CL2008003782A1 (en) Biospecific bivalent antibody that comprises the heavy and light chain of an antibody that binds to a first antigen where the ch3 domain is replaced by ch1, and the heavy and light chain of an antibody that binds to a second antigen, in which the ch3 domain is replaced by cl; Preparation method; and composition.
PE20121552A1 (en) MATURE AFFINITY HUMANIZED ANTI-CEA MONOCLONAL ANTIBODIES
UY30260A1 (en) ANTIBODIES DIRECTED AGAINST UPAR AND USES OF THE SAME
AR075604A1 (en) ANTIBODIES AGAINST A LINK THAT INDUCES PROLIFERATION (APRIL)
PE20110306A1 (en) HUMAN ANTIBODIES THAT JOIN LYMPHOCYTARY ACTIVATION GEN 3 (LAG-3)
ES2572177T3 (en) Human anti-B7RP1 neutralizing antibodies
PE20061323A1 (en) ANTIBODIES TARGETED AGAINST AMYLOID BETA PEPTIDE AND METHODS USING THEM
AR096895A2 (en) ANTIBODY THAT Binds TO THE CYTOQUINE, THYMPIC STROMAL LYMPHOPOYETIN (TSLP)
PE20131209A1 (en) ANTI-FAP ANTIBODIES
PE20140196A1 (en) ANTI-CD37 ANTIBODIES
PE20180042A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM
RS53042B (en) Antibodies against erbb3 and uses thereof
MY166776A (en) Humanised anti-ctla4 antibodies
PE20120340A1 (en) ANTI-TUMOR COMBINATIONS CONTAINING ANTIBODIES THAT SPECIFICALLY RECOGNIZE CD38 AND MELFALAN
PE20081478A1 (en) CD44 ANTIBODIES
PE20140247A1 (en) ANTI-CD38 ANTIBODIES

Legal Events

Date Code Title Description
FB Suspension of granting procedure